About Takeda Pharmaceutical
Millennium Pharmaceuticals was established in 1993 as a genomics company, applying world-class molecular biology and genomic technologies to the discovery and development of new therapies in a broad spectrum of diseases. Over time we evolved into a fully integrated biopharmaceutical company.
In May 2008, Millennium was acquired by Takeda Pharmaceutical Company Limited in Japan and became known as Millennium: The Takeda Oncology Company (Millennium), a wholly-owned subsidiary of Takeda that served as the organization’s global center of excellence in oncology.
The combination of oncology resources resulted in a robust pipeline that addresses a broad range of cancers. Our focus is to improve the treatment of cancer, which gives us an important oncology mission to deliver extraordinary medicines to patients with cancer worldwide through our science, innovation and passion, toward an ultimate goal and aspiration to cure cancer.
In May 2013, the decision was made to fully integrate Millennium into the global Takeda R&D engine to maximize the resources available from the broader Takeda organization and to realize greater operational efficiencies. The R&D and G&A functions in Boston became known publically as Takeda Pharmaceuticals International Co. The oncology Commercial, Business Development and Patient Advocacy divisions continue to operate as Millennium: The Takeda Oncology Company.
At Takeda and Millennium, we want to exceed expectations in terms of progress against cancer, distinguishing ourselves within the research-based biopharmaceutical community. We’re prepared to deliver on this goal by focusing on novel or best-in-class drug candidates, and cultivating the brightest talent. This puts Takeda on an exciting path toward global oncology leadership.
We help drive and accelerate the progress that continually is being made against cancer; these advances, sometimes big breakthroughs and sometimes incremental, make a real difference in the lives of patients. We won’t be satisfied until cures are found and the threat is removed. People who battle cancer deserve no less.
Our goal also is to provide patients and people close to them with easily understandable information about the diseases our products treat, as well as other relevant information and service resources. We also provide information about our investigational drugs that are approaching or in development, our clinical trials, and what patients, caregivers and healthcare providers need to know about our assistance and access programs for any drug we currently market. We work toward our goals with the same urgency for patients that we would for our families. We strive to earn the respect and admiration of the global oncology community by delivering significant progress against cancer while living our core values.
The people and culture at Takeda and Millennium make all the difference.
Our work is more than a job. We are entrepreneurial about both our work and achieving progress. We focus on what’s important and timely decision-making.
As a site based in New England, we enjoy our local community and contribute in many ways to local business, social and environmental causes. We offer a broad range of opportunities for campus-based employees to participate. We also involve ourselves on a corporate level in matters of social responsibility.
June 12, 1781
Founder: Chobei Takeda
CEO: Christophe Weber
CMO (Medical) and CSO (Scientific): Andrew Plump
CFO: James Kehoe
Tweets by Takeda
1248 articles with Takeda Pharmaceutical
CNDAP Partners with Takeda to Develop New Therapies for Alzheimer's Disease and Related Brain Disorders
Cure Network Dolby Acceleration Partners LLC and Takeda Pharmaceutical Company Limited have entered into a research collaboration to develop small molecules targeting tau, a protein involved in Alzheimer's disease and other major brain disorders.
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.
Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder
Codexis, Inc. announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited for the research and development of an additional gene therapy for a lysosomal storage disorder bringing the total number of programs under the agreement to four.
Phase 3 Clinical Trial Subgroup Analysis Across Solid Organ Transplant (SOT) Types Supports Efficacy of Maribavir Over Conventional Therapies in Post-Transplant Recipients With Cytomegalovirus Infection (Refractory, With or Without Resistance)
Takeda Pharmaceutical Company Limited at the American Transplant Congress 2021 Virtual Connect presented results from a new subgroup analysis of SOT recipients in the Phase 3 TAK-620-303 trial, for the investigational drug TAK-620.
Emergent said the vaccine candidate against the mosquito-borne illness showed an increase in immune response as measured by anti-chikungunya virus SNA.
Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
Dengue is the fastest-spreading mosquito-borne viral disease with an estimated 390 million cases and 500,000 hospitalizations per year globally, with limited options for prevention
Takeda Pharmaceutical Company Limited announced that the Ministry of Health, Labour and Welfare granted special approval under article 14-3 of the Pharmaceuticals and Medical Devices Act for emergency use of Moderna’s mRNA COVID-19 vaccine, TAK-919, now known as COVID-19 Vaccine Moderna Intramuscular Injection, in Japan.
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatment
Takeda Pharmaceutical Company Limited announced that the U.S. Food & Drug Administration has accepted a New Drug Application for maribavir for the treatment of CMV infection in those that are refractory with or without resistance, in solid organ transplant or hematopoietic cell transplant recipients.
5/21/2021If approved, Takeda said Maribavir would become the first and only treatment indicated for CMV infection in refractory patients.
Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CML
Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG ® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CML – OPTIC Trial Evaluating Response-Based Dosing Regimens of ICLUSIG for the Treatment of Resistant / Intolerant Chronic-Phase CML Demonstrates Durable, Clinically Meaningful Depth of Response While Managing Arterial Occlusive Event Risk
Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC
− Mobocertinib, an Oral Targeted Therapy, Demonstrated a Median Overall Survival of 24 Months, and Responses were Observed across Diverse EGFR Exon20 Insertion Variants − Results Included in Mobocertinib’s New Drug Application (NDA), which was Recently Granted Priority Review by the U.S. Food and Drug Administration (FDA)
Takeda Delivers Resilient FY2020 Results With Strong Margins & Robust Cashflow; Underlying Revenue Growth Expected to Accelerate in FY2021
Over the course of FY2020, Takeda remained resilient as we operated in new ways through the COVID-19 pandemic.
BioSpace takes an in-depth look at the Top 25 of Q1.
Takeda Manufacturing Facilities in Japan and Ireland Recognized With Category Awards for 2021 Facilities of the Year
Both Awards, Issued by the International Society for Pharmaceutical Engineering (ISPE), Underscore Takeda’s Leadership in Digital and Innovative Technologies New Solid Pharmaceutical Packaging Building With Automatic Line Clearance in Hikari, Japan, Wins Process Intelligence and Innovation Award
Centogene N.V. announced that it has extended its partnership with Takeda Pharmaceutical Company Limited to diagnose patients with certain genetic disorders.
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it will host a conference call on April 6, 2021 to provide updates on select New Molecular Entities (NMEs) in its Wave 1 pipeline portfolio. With several NME regulatory filings expected by year-end FY2021, the company will outline plans for organic and sustainable revenue growth over the next several years.
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Orifarm Group (“Orifarm”) for a total value of up to $670 million USD. The portfolio includes approximately 130 over-the-counter (OTC) and prescription pharmaceutical products sold in Europe, and two manufacturing sites located in Denmark and Poland.
Takeda Pharmaceutical Company Limited announced the completion of its previously-announced sale of Takeda Consumer Healthcare Company Limited to Oscar A-Co KK, a company controlled by funds managed by The Blackstone Group Inc. and its affiliates for a total value of JPY 242.0 billion1.
BridGene Biosciences Announces Research Collaboration with Takeda to Discover Small Molecule Drugs for Undruggable Targets
BridGene Biosciences, Inc. , a biotechnology company using cutting-edge technology to discover and develop small molecules for hard-to-drug therapeutic targets, announced today a strategic research collaboration with Takeda Pharmaceutical
The companies will harness BridGene’s IMTAC (Isobaric Mass Tagged Affinity Characterization) Chemoproteomics platform to identify targets and small molecule drug candidates.